Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043849 · ClinicalTrials.gov registry record · Phase 4
Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
A Phase 4 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT00043849 is a Phase 4 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 60 participants.
The verdict
NCT00043849, a Phase 4 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary aim of this study is to determine the safety and efficacy of quetiapine (Seroquel) for the treatment of psychosis and/or agitation in patients with primary dementia complicated by coexistent parkinsonism, or patients with Parkinson's disease with dementia \[PDD\] who have episodes of agitation or psychosis. The secondary aim is to determine the safety and tolerability, particularly the influence on parkinsonism, of quetiapine when used to treat psychosis and/or agitation in patients with dementia complicated by coexistent parkinsonism.
Interventions
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043849
The ClinicalTrials.gov registry entry for NCT00043849 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quetiapine is the first listed.
NCT00043849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00043849 about?
NCT00043849 is a clinical study titled "Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)". The primary aim of this study is to determine the safety and efficacy of quetiapine (Seroquel) for the treatment of psychosis and/or agitation in patients with primary dementia complicated by coexistent parkinsonism, or patients with Parkinson's disease with dementia \[PDD\] who have episodes of agi...
What is the current status of trial NCT00043849?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2002-07. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00043849?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00043849?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.